234
Views
5
CrossRef citations to date
0
Altmetric
Drug Profile

Budesonide/formoterol in the treatment of asthma

, &
Pages 557-566 | Published online: 09 Jan 2014

References

  • Partridge M, van der Molen T, Myrseth S-E, Busse W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm. Med.6(1), 13 (2006).
  • Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur. Respir. J.19(1), 182–191 (2002).
  • Sovani MP, Whale CI, Oborne J et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help? Br. J. General Pract.58, 37–43 (2008).
  • Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs64(14), 1597–1618 (2004).
  • Issar M, Sahasranaman S, Buchwald P, Hochhaus G. Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur. Respir. J.27(3), 511–516 (2006).
  • Adams N, Bestall J, Jones PW. Budesonide at different doses for chronic asthma. Cochrane Database Syst. Rev.4, CD003271 (2001).
  • Oborne J, Mortimer K, Hubbard RB, Tattersfield AE, Harrison TW. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am. J. Respir. Crit. Care Med.180(7), 598–602 (2009).
  • Juniper E, Kline P, Vanzieleghem M et al. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur. Respir. J.3(10), 1122–1127 (1990).
  • Kips JC, O’Connor BJ, Inman MD et al. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am. J. Respir. Crit. Care Med.161(3), 996–1001 (2000).
  • Sears MR, Lotvall J. Past, present and future – β2-adrenoceptor agonists in asthma management. Respir. Med.99(2), 152–170 (2005).
  • Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lotvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm. Pharmacol. Ther.14(1), 29–34 (2001).
  • Lotvall J, Ankerst J. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients. Respir. Med.102(3), 449–456 (2008).
  • Totterman K, Huhti L, Sutinen E et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur. Respir. J.12(3), 573–579 (1998).
  • Cheung D, van Klink HC, Aalbers R. Improved lung function and symptom control with formoterol on demand in asthma. Eur. Respir. J.27(3), 504–510 (2006).
  • Lindmark B. Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma. Ther. Adv. Respir. Dis.2(5), 279–299 (2008).
  • Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med.160(1), 244–249 (1999).
  • Maneechotesuwan K, Essilfie-Quaye S, Meah S et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest128(4), 1936–1942 (2005).
  • Usmani OS, Ito K, Maneechotesuwan K et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am. J. Respir. Crit. Care Med.172(6), 704–712 (2005).
  • Eklund A, Tronde A, Johannes-Hellberg I, Gillen M, Borgstrom L. Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults. Biopharm. Drug Dispos.29(7), 382–395 (2008).
  • Harrison TW, Tattersfield AE. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax58(3), 258–260 (2003).
  • McGavin JK, Goa KL, Jarvis B. Inhaled budesonide/formoterol combination. Drugs61(1), 71–78; discussion 79–80 (2001).
  • Tronde A, Gillen M, Borgstrom L, Lotvall J, Ankerst J. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD. J. Clin. Pharmacol.48(11), 1300–1308 (2008).
  • Ni Chroinin M, Greenstone IR, Danish A et al. Long-acting β2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst. Rev.4, CD005535 (2005).
  • Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of inhaled long-acting β2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst. Rev.4, CD005307 (2009).
  • Noonan M, Rosenwasser LJ, Martin P, O’Brien CD, O’Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs66(17), 2235–2254 (2006).
  • Corren J, Korenblat PE, Miller CJ, O’Brien CD, Mezzanotte WS. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin. Ther.29(5), 823–843 (2007).
  • Zetterstrom O, Buhl R, Mellem H et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur. Respir. J.18(2), 262–268 (2001).
  • Buhl R, Creemers JP, Vondra V et al. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir. Med.97(4), 323–330 (2003).
  • Kuna P, Creemers JP, Vondra V et al. Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma. Respir. Med.100(12), 2151–2159 (2006).
  • Lalloo UG, Malolepszy J, Kozma D et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest123(5), 1480–1487 (2003).
  • O’Byrne PM, Bisgaard H, Godard PP et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am. J. Respir. Crit. Care Med.171(2), 129–136 (2005).
  • Fitzgerald JM, Sears MR, Boulet LP et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can. Respir. J.10(8), 427–434 (2003).
  • Canonica GW, Castellani P, Cazzola M et al. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulm. Pharmacol. Ther.17(4), 239–247 (2004).
  • Ind PW, Haughney J, Price D, Rosen JP, Kennelly J. Adjustable and fixed dosing with budesonide/ formoterol via a single inhaler in asthma patients: the ASSURE study. Respir. Med.98(5), 464–475 (2004).
  • Aalbers R, Backer V, Kava TT et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr. Med. Res. Opin.20(2), 225–240 (2004).
  • Fitzgerald JM, Boulet LP, Follows RM. The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin. Ther.27(4), 393–406 (2005).
  • Scicchitano R, Aalbers R, Ukena D et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr. Med. Res. Opin.20(9), 1403–1418 (2004).
  • Vogelmeier C, D’Urzo A, Pauwels R et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur. Respir. J.26(5), 819–828 (2005).
  • Rabe KF, Pizzichini E, Stallberg B et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest129(2), 246–256 (2006).
  • Lundborg M, Wille S, Bjermer L et al. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost–effectiveness study. Curr. Med. Res. Opin.22(5), 809–821 (2006).
  • Rabe KF, Atienza T, Magyar P et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet368(9537), 744–753 (2006).
  • Bousquet J, Boulet LP, Peters MJ et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir. Med.101(12), 2437–2446 (2007).
  • Kuna P, Peters MJ, Manjra AI et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int. J. Clin. Pract.61(5), 725–736 (2007).
  • Demoly P, Louis R, Soes-Petersen U et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respir. Med.103(11), 1623–1632 (2009).
  • Pavord ID, Jeffery PK, Qiu Y et al. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. J. Allergy Clin. Immunol.123(5), 1083–1089 (2009).
  • Edwards SJ, Maltzahn Rv, Naya IP, Harrison T. Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials. Int. J. Clin. Pract.64(5), 619–627 (2010).
  • Boonsawat W, Charoenratanakul S, Pothirat C et al. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir. Med.97(9), 1067–1074 (2003).
  • Balanag VM, Yunus F, Yang PC, Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm. Pharmacol. Ther.19(2), 139–147 (2006).
  • Bateman ED, Fairall L, Lombardi DM, English R. Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respir. Res.7, 13 (2006).
  • Mortimer KJ, Harrison TW, Tang Y et al. Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. Br. J. Clin. Pharmacol.62(4), 412–419 (2006).
  • Donnelly R, Williams KM, Baker AB et al. Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose-response study. Am. J. Respir. Crit. Care Med.156(6), 1746–1751 (1997).
  • Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K. Safety of inhaled corticosteroids. Proc. Am. Thorac.Soc.1(3), 171–175 (2004).
  • Sovani MP, Whale CI, Tattersfield AE. A benefit–risk assessment of inhaled long-acting β2-agonists in the management of obstructive pulmonary disease. Drug Saf.27(10), 689–715 (2004).
  • Mortimer KJ, Tattersfield AE. Benefit versus risk for oral, inhaled, and nasal glucocorticosteroids. Immunol. Allergy Clin. North Am.25(3), 523–539 (2005).
  • Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial. Chest129(1), 15–26 (2006).
  • Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst. Rev.4, CD006923 (2008).
  • Bateman E, Nelson H, Bousquet J et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann. Intern. Med.149(1), 33–42 (2008).
  • Nelson H, Bonuccelli C, Radner F et al. Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials. J. Allergy Clin. Immunol.125(2), 390–396.e8 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.